NCT04493151View on ClinicalTrials.gov

Imipenem/Cilastatin/Relebactam PK in ECMO

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

May 31, 2023

Study Completion Date

June 30, 2023

Conditions
Sepsis
Interventions
DRUG

Imipenem, Cilastatin and Relebactam

After receipt of imipenem-cilastatin-relebactam, ten blood samples will be collected to determine the pharmacokinetics of imipenem and relebactam.

Trial Locations (1)

06102

Hartford Hospital, Hartford

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Joseph L. Kuti, PharmD

OTHER

NCT04493151 - Imipenem/Cilastatin/Relebactam PK in ECMO | Biotech Hunter | Biotech Hunter